FDMT

10.1904.94%
DH

David H. Kirn

Co-Founder, President, CEO & Director

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc. He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013 and serves as its President since January 01, 2026. Dr. Kirn served as President of 4D Molecular Therapeutics, Inc. since 2020 and has been its Director since September 12, 2013. He served as Chairman of 4D Molecular Therapeutics, Inc. since 2013 until August 2020. He serves as Executive Chairman of the board of the following privately held company: Ignite Immunotherapy Inc., where he is a co-founder. He is Member of Scientific Advisory Board of Dispatch Biotherapeutics, Inc. He Founded Jennerex Biotherapeutics, Inc. and served as its Chief Medical Officer and President of Research and Development. Dr. Kirn served as the Chief Executive Officer and President at Jennerex Biotherapeutics, Inc. Dr. Kirn is a medical oncologist and a leader in cancer product research and commercial development. He held academic positions at Harvard Medical School; the University of California Berkeley, San Francisco and the University of Oxford. He Co-founded the International Society of Oncolytic Virotherapy in 2007. Dr. Kirn served as Vice President of Clinical Research at Onyx Pharmaceuticals. After joining as the first oncology development employee, he created and initiated clinical development plans in partnership with Bayer for Nexavar. He also led the development of a first-in-class oncolytic virus therapeutic through to Phase III and a corporate partnership with Warner-Lambert. Dr. Kirn held senior development positions at Celgene. He was a senior advisor on viral vector gene therapeutics and cancer immunotherapy with numerous companies, including Biogen Idec, Novartis, Cell Genesys, Pfizer and Bayer. He was an invited advisor on cancer therapy to the National Institutes of Health (U.S.), the Gene Therapy Advisory Committee (U.K.) and the European Agency for the Evaluation of Medicinal Products (E.U.). He served as Director of Jennerex Biotherapeutics, Inc. He is author of over 70 publications in peer-reviewed journals and textbooks. Dr. Kirn received a B.A. in Physiology (Departmental Citation; Phi Beta Kappa) from U.C. Berkeley in 1985, an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women’s Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at U.C. San Francisco and completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. Dr. Kirn is an Adjunct Professor of Bioengineering at U.C. Berkeley. In 2013, he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.

Positions